Back to search results

Meloxicam for Postoperative Pain After Mohs Surgery

This study is looking for better ways to manage pain after Mohs micrographic surgery (a precise surgery for skin cancer). Researchers want to see if Meloxicam, a type of pain reliever, works better than the usual care. You could receive a single dose of either 7.5 mg or 15 mg of Meloxicam, followed by acetaminophen. Another group will receive acetaminophen followed by alternating ibuprofen and acetaminophen, which is the standard treatment. The study will compare your pain levels from when you join until about 7 to 21 days later, when your stitches are removed or wound is checked. This study aims to improve comfort and well-being for patients. Anyone aged 18 to 110 years old who is having Mohs surgery at the University of Oklahoma can join, unless they are pregnant or planning to be.

Study design
This interventional study plans to enroll 300 participants. It compares three different pain management approaches after Mohs surgery.
What's involved
You would receive a mandatory dose of one of the study medications after your Mohs surgery. Your pain levels will be monitored from enrollment until about 7 to 21 days later.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed from enrollment until suture removal, wound check, or flap takedown, which is between 7 and 21 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07200544

Meloxicam in Mohs Micrographic Surgery

Recruiting
PHASE4Ages 18+InterventionalPrevention
University of Oklahoma
~300 participants
Updated 2025-12-15 on ClinicalTrials.gov
What's tested:Meloxicam 7.5 mgMeloxicam 15 mgAcetaminophen 500mg

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To evaluate the effect of the use of Meloxicam vs SoC on post-operative pain levels in participants undergoing Mohs micrographic surgery.
Measured over From enrollment to suture removal, wound check or flap takedown (7-21 days)

Conditions

Postoperative Pain, Acute
Skin Cancer

Explore related trials

Malignant Skin NeoplasmPost-Operative Pain

Where it's being run

1 sites across 1 states
Oklahoma1

Study leadership

  • Lindsey Collins, MD · PRINCIPAL_INVESTIGATOR · University of Oklahoma, Department of Dermatology

Who to contact

Chase Pitchford, MD
[email protected]
405-271-6110
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All adult patients who consents to the study and are undergoing Mohs micrographic surgery at the University of Oklahoma.

Exclusion

Women who are pregnant, suspected to be pregnant, or planning to become pregnant during the study period will be excluded from participation.
Chronic liver disease (chronic hepatitis, acute hepatitis, cirrhosis, NASH, NAFLD, alcoholic liver disease, hemochromatosis, Wilson's disease)
Chronic kidney disease stage III or greater,
Aspirin-sensitive asthma
History of chronic NSAID use
Patients vulnerable to drug interactions
GI bleeds
Peptic ulcers
Non-English speakers

What this trial measures

  • To evaluate the effect of the use of Meloxicam vs SoC on post-operative pain levels in participants undergoing Mohs micrographic surgery.From enrollment to suture removal, wound check or flap takedown (7-21 days)

    Pain levels at specified times post-operation (POD 0 and POD 1) will be compared among the three treatment groups. This will be collected via the Numeric Pain Scale, a 0-10 scale using descriptives faces to assess pain by the patient.